U.S. markets closed

PerkinElmer, Inc. (PKN.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
102.00-1.00 (-0.97%)
At close: 4:53PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close103.00
Open103.00
Bid0.00 x 30000
Ask0.00 x 30000
Day's Range102.00 - 105.00
52 Week Range59.50 - 136.00
Volume48
Avg. Volume154
Market Cap11.616B
Beta (5Y Monthly)1.13
PE Ratio (TTM)15.70
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.23 (0.23%)
Ex-Dividend DateApr 15, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Why Is PerkinElmer (PKI) Down 9.6% Since Last Earnings Report?
      Zacks

      Why Is PerkinElmer (PKI) Down 9.6% Since Last Earnings Report?

      PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    • Moody's

      PerkinElmer, Inc. -- Moody's assigns Baa3 rating to PerkinElmer's notes offering

      Rating Action: Moody's assigns Baa3 rating to PerkinElmer's notes offeringGlobal Credit Research - 04 Mar 2021New York, March 04, 2021 -- Moody's Investors Service, ("Moody's") assigned a Baa3 rating to the proposed offering of senior unsecured 10- and 30-year notes of PerkinElmer, Inc. ("PerkinElmer"). There are no changes to Moody's existing ratings of PerkinElmer including the Baa3 senior unsecured long-term rating. The acquisition slightly increases PerkinElmer's financial leverage to close to 3.0x, up from 2.5x in the last twelve months to September 30, 2020.

    • Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio
      Zacks

      Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio

      Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.